Small Molecule-Mediated TGF-beta Type II Receptor Degradation Promotes Cardiomyogenesis in Embryonic Stem Cells.

Journal: 
Cell Stem Cell
Publication Year: 
2012
Authors: 
Erik Willems , Joaquim Cabral-Teixeira , Dennis Schade , Wenqing Cai , Patrick Reeves , Paul J Bushway , Marion Lanier , Christopher Walsh , Tomas Kirchhausen , Juan Carlos Izpisua Belmonte , John Cashman , Mark Mercola
Public Summary: 
The cellular signals controlling the formation of cardiomyocytes, vascular smooth muscle, and endothelial cells from stem cell-derived mesoderm are poorly understood. We didscovered ITD-1 as a highly selective TGF-beta inhibitor that induces cardiomyocyte differentiation from multipotent cardiovascular precursors.
Scientific Abstract: 
The cellular signals controlling the formation of cardiomyocytes, vascular smooth muscle, and endothelial cells from stem cell-derived mesoderm are poorly understood. To identify these signals, a mouse embryonic stem cell (ESC)-based differentiation assay was screened against a small molecule library resulting in a 1,4-dihydropyridine inducer of type II TGF-beta receptor (TGFBR2) degradation-1 (ITD-1). ITD analogs enhanced proteasomal degradation of TGFBR2, effectively clearing the receptor from the cell surface and selectively inhibiting intracellular signaling (IC(50) approximately 0.4-0.8 muM). ITD-1 was used to evaluate TGF-beta involvement in mesoderm formation and cardiopoietic differentiation, which occur sequentially during early development, revealing an essential role in both processes in ESC cultures. ITD-1 selectively enhanced the differentiation of uncommitted mesoderm to cardiomyocytes, but not to vascular smooth muscle and endothelial cells. ITD-1 is a highly selective TGF-beta inhibitor and reveals an unexpected role for TGF-beta signaling in controlling cardiomyocyte differentiation from multipotent cardiovascular precursors.

© 2013 California Institute for Regenerative Medicine